Michael Bolton is ready to discuss his ongoing battle with an aggressive form of brain cancer: 'Succumbing to the challenge ...

While chemotherapy, radiation, and surgeries are common for most cancer treatments, immunotherapy is continuing to allow some ...

Nivolumab is a monoclonal antibody that works by binding to a protein called PD-1 on a type of immune cell called T-cell.

The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found.

Michael Bolton opened up for the first time about his battle with glioblastoma, a rare and aggressive form of brain cancer, over a year after sharing his brain tumor diagnosis.

Princess Margaret Cancer Center at University Health Network-led researchers constructed a detailed single-cell atlas of ...

It's been more than a year since the singer was diagnosed with an aggressive form of cancer, but he says he's choosing to ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

Monitoring blood levels of circulating tumor DNA in patients with stage 3 melanoma may accurately predict skin cancer ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Michael Bolton, 72, reflects on his glioblastoma brain cancer diagnosis, surgery and recovery journey with his family's support ...

Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.